[go: up one dir, main page]

MX2012001991A - Factor de velocidad. - Google Patents

Factor de velocidad.

Info

Publication number
MX2012001991A
MX2012001991A MX2012001991A MX2012001991A MX2012001991A MX 2012001991 A MX2012001991 A MX 2012001991A MX 2012001991 A MX2012001991 A MX 2012001991A MX 2012001991 A MX2012001991 A MX 2012001991A MX 2012001991 A MX2012001991 A MX 2012001991A
Authority
MX
Mexico
Prior art keywords
velocity factor
antibodies
antigen
determinations
velocity
Prior art date
Application number
MX2012001991A
Other languages
English (en)
Inventor
Michael Schraeml
Leopold Von Proff
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012001991A publication Critical patent/MX2012001991A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con el factor de velocidad. Con base en el factor de velocidad los anticuerpos se pueden clasificar, es decir, los anticuerpos se pueden caracterizar con respecto a sus propiedades de unión como, por ejemplo, un aglutinante antigénico entrópico o entálpico. Una clasificación basada en factor de velocidad no requiere determinación termodinámica y/o cálculos detallados. El factor de velocidad es la relación de las constantes ka de velocidad de asociación del complejo antígeno-anticuerpo determinado a 37°C y a 13°C. Dado que solo se requieren dos determinaciones experimentales para calcular el factor de velocidad, este es un método adecuado rápido y de alto rendimiento.
MX2012001991A 2009-08-25 2010-08-19 Factor de velocidad. MX2012001991A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09010844 2009-08-25
PCT/EP2010/062115 WO2011023623A1 (en) 2009-08-25 2010-08-19 Velocity factor

Publications (1)

Publication Number Publication Date
MX2012001991A true MX2012001991A (es) 2012-02-29

Family

ID=41311668

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015013631A MX357102B (es) 2009-08-25 2010-08-19 Metodo para obtener anticuerpos.
MX2012001991A MX2012001991A (es) 2009-08-25 2010-08-19 Factor de velocidad.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015013631A MX357102B (es) 2009-08-25 2010-08-19 Metodo para obtener anticuerpos.

Country Status (13)

Country Link
US (3) US8617849B2 (es)
EP (1) EP2470563B1 (es)
JP (1) JP5412579B2 (es)
KR (1) KR101484375B1 (es)
CN (1) CN102482344B (es)
AU (1) AU2010288663B2 (es)
BR (1) BR112012002248A2 (es)
CA (1) CA2770173C (es)
ES (1) ES2577579T3 (es)
IL (2) IL217242A (es)
MX (2) MX357102B (es)
SG (1) SG178546A1 (es)
WO (1) WO2011023623A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553204T3 (es) 2008-08-27 2015-12-07 F. Hoffmann-La Roche Ag Procedimiento para el cribado de anticuerpos de alta afinidad
ES2577579T3 (es) * 2009-08-25 2016-07-15 F. Hoffmann-La Roche Ag Factor de velocidad
EP3360570A1 (en) 2017-02-13 2018-08-15 Roche Diagnostics GmbH Antibodies recognizing genetic variants
EP4430074A1 (en) 2021-11-11 2024-09-18 F. Hoffmann-La Roche AG Novel monoclonal antibodies directed against l-thyroxine and diagnostic uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242190B1 (en) * 1999-12-01 2001-06-05 John Hopkins University Method for high throughput thermodynamic screening of ligands
DE10005301A1 (de) * 2000-02-07 2001-08-09 Trutnau Hans Heinrich Multi-Schritt-Kinetik molekularer Interaktionen als analytisches Mess- und Auswerte-Verfahren
US20050175999A1 (en) 2001-08-30 2005-08-11 Klakamp Scott L. Methods for determining binding affinities
JP4178514B2 (ja) 2003-06-27 2008-11-12 東洋紡績株式会社 抗体のスクリーニング方法
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
JP5052509B2 (ja) 2005-06-13 2012-10-17 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ アフィニティ分析法及びシステム
AU2006277086A1 (en) 2005-08-05 2007-02-15 National University Of Singapore Novel anticoagulant polypeptides and complex
EA017303B1 (ru) 2006-05-25 2012-11-30 Глаксо Груп Лимитед Модифицированные гуманизированные антитела против интерлейкина-18 и их применение
JP4583356B2 (ja) 2006-10-30 2010-11-17 株式会社アルバック 結合素子、バイオセンサ及び生体物質間の相互作用測定方法
ES2553204T3 (es) * 2008-08-27 2015-12-07 F. Hoffmann-La Roche Ag Procedimiento para el cribado de anticuerpos de alta afinidad
ES2577579T3 (es) * 2009-08-25 2016-07-15 F. Hoffmann-La Roche Ag Factor de velocidad

Also Published As

Publication number Publication date
CA2770173C (en) 2018-04-24
US20170212107A1 (en) 2017-07-27
US8617849B2 (en) 2013-12-31
CA2770173A1 (en) 2011-03-03
BR112012002248A2 (pt) 2016-06-14
ES2577579T3 (es) 2016-07-15
JP2013501819A (ja) 2013-01-17
US9488661B2 (en) 2016-11-08
US20140256915A1 (en) 2014-09-11
MX357102B (es) 2018-06-26
KR101484375B1 (ko) 2015-01-19
EP2470563B1 (en) 2016-04-13
EP2470563A1 (en) 2012-07-04
WO2011023623A1 (en) 2011-03-03
CN102482344A (zh) 2012-05-30
US20120156726A1 (en) 2012-06-21
US10877030B2 (en) 2020-12-29
SG178546A1 (en) 2012-03-29
IL217242A (en) 2016-08-31
JP5412579B2 (ja) 2014-02-12
AU2010288663B2 (en) 2016-02-25
IL217242A0 (en) 2012-02-29
AU2010288663A1 (en) 2012-02-02
IL246733B (en) 2018-04-30
CN102482344B (zh) 2014-09-17
KR20120038522A (ko) 2012-04-23

Similar Documents

Publication Publication Date Title
IL275114B (en) Antibody constructs for cdh19 and cd3 binding sites, preparations containing them, methods for their preparation and uses thereof
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
AU2017204797B2 (en) Antibodies with modified isoelectric points
WO2013041844A3 (en) Antibodies, variable domains & chains tailored for human use
MY156315A (en) Anti-vegf antibodies
WO2012088302A3 (en) Half immunoglobulin binding proteins and uses thereof
CY1122978T1 (el) Αντισωματα εναντι-vla-4
GB201212940D0 (en) Antibodies to highly conserved targets
GB2468232A (en) Antigen-bindng constructs
WO2015013388A3 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
IL202322A0 (en) Detection of antigens carried by erythrocytes and of anti-erythrocyte antibodies
WO2011133704A3 (en) Modified polypeptides and proteins and uses thereof
EP4356927A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
GB201108236D0 (en) Method
DK2681244T3 (da) Cea-antistoffer
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
WO2014205248A3 (en) Mechanical characterization of core samples
WO2012125733A3 (en) Antibody screening methods
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2014043509A3 (en) Single domain antibody with c-terminal modification
WO2011085165A3 (en) Ca-125 immune complexes as biomarkers of ovarian cancer
MX2012001991A (es) Factor de velocidad.
IN2014MN01868A (es)

Legal Events

Date Code Title Description
FG Grant or registration